

March 24-25, 2023

GLOBAL WEB-CONFERENCE ON CARDIO-RENAL-METABOLIC

3rd edition

SCIENTIFIC PROGRAM

March 24-25, 2023

March 24, 2023 (Day 1)			
Local time	Asia (Bangkok UTC+7)	Europe/Middle East (Paris UTC+2)	Americas (Rio UTC-3)
2:20-2:50 pm		Meet-the-expert session Management of heart failure in real world clinical practice – insights from the REWOLUTION HF surveys	
3:00-4:00 pm	Plenary session 1 HFpEF	Plenary session 3 Weight management in CRM disease	Plenary session 5 Mineralocorticoids antagonists in CRM disease
4:10-4:50 pm	Satellite symposium SGLT2 inhibitors in cardio-renal-metabolic patients – the perfect fit?	Meet-the-expert session Implementation patterns and challenges in HF care: insights from the EVOLUTION HF study	Meet-the-expert session Single pill combination (SPC) in Cardiorenal metabolic (CRM) disease
5:00-6:00 pm	Plenary session 2 SGLT2 updates	Plenary session 4 Guidelines implementation for acutely ill patients	Plenary session 6 Diuretics: old drugs, new data, new approaches

March 25, 2023 (Day 2)			
Local time	Asia (Bangkok UTC+7)	Europe/Middle East (Paris UTC+2)	Americas (Rio UTC-3)
2:20-2:50 pm		Meet-the-expert session Management of hyperkalemia in cardiorenal disease – practical guidance and novel therapeutic options	
3:00-4:00 pm	Plenary session 7 CRM drug management in patients with low eGFR and type 2 diabetes	Plenary session 9 Managing “metals”	Plenary session 5 Mineralocorticoids antagonists in CRM disease
4:10-4:50 pm	Satellite symposium Management of CKD without diabetes – SGLT2 inhibitors, the new standard of care	Satellite symposium Management of Hyperkalemia across the cardiorenal spectrum	Meet-the-expert session Management of heart failure in real world clinical practice – insights from the REWOLUTION HF surveys
5:00-6:00 pm	Plenary session 8 Diabetes and cardio-renal disease: the relevance of early treatment with the right drug	Plenary session 4 Guidelines implementation for acutely ill patients	Plenary session 6 Diuretics: old drugs, new data, new approaches

Bangkok Time (ICT)	Paris Time (CET)	Rio Time (BRT)	Part 1
15:00-16:00	09:00-10:00	05:00-06:00	Session 1 - HFpEF <i>Chairs: Andrew J. S. Coats, Melbourne, Australia & Giuseppe Rosano, London, UK</i> Epidemiology and clinical features <i>Giuseppe Rosano, London, UK</i> Diabetes as a key risk factor for HFpEF <i>Eberhard Standl, Munich, Germany</i> HFpEF and chronic kidney disease: one and the same? <i>María José Soler, Barcelona, Spain</i> Management with new drugs and devices <i>Stefan D. Anker, Berlin, Germany</i> Panel discussion
			Break
			Satellite symposium - SGLT2 inhibitors in cardio-renal-metabolic patients – the perfect fit? <i>Chair: Michel Jadoul, Brussels, Belgium</i> SGLT2 inhibitors – the perfect fit for cardio-metabolic patients? <i>Paola Fioretto, Padova, Italy</i> SGLT2 inhibitors – the perfect fit for cardio-renal patients? <i>Stefan D. Anker, Berlin, Germany</i> SGLT2 inhibitors – the perfect fit for renal-metabolic patients? <i>Michel Jadoul, Brussels, Belgium</i> Panel discussion <i>Supported by an educational grant from the Boehringer Ingelheim & Lilly Alliance</i>
			Break
			Session 2 - SGLT2 updates <i>Chairs: Andrew J. S. Coats, Melbourne, Australia & Hiddo Heerspink, Groningen, The Netherlands</i> Focus on diabetology <i>Antonio Ceriello, Barcelona, Spain</i> Focus on cardiology <i>Gianluigi Savarese, Stockholm, Sweden</i> Focus on nephrology <i>Christoph Wanner, Würzburg, Germany</i> Panel discussion
20:20-20:50	14:20-14:50	10:20-10:50	Part 2
			Meet-the-expert session - Management of heart failure in real world clinical practice – insights from the REWOLUTION HF surveys <i>Andrew J. S. Coats, Melbourne, Australia & Ewa Jankowska, Wrocław, Poland</i>
			Break
			Session 3 - Weight management in CRM disease <i>Chairs: Luc Van Gaal, Antwerp, Belgium & Wolfram Döhner, Berlin, Germany</i> Obesity and CRM disease: epidemiology and pathophysiology <i>Milton Packer, Dallas, TX, USA</i> Weight control in diabetes: new strategies and outcomes <i>Carel W. le Roux, Dublin, Ireland</i> Bariatric surgery <i>Tammy L. Kindel, Milwaukee, WI, USA</i> Weight control therapies: effects on BP, kidney and CV outcomes <i>Ildiko Lingvay, Dallas, TX, USA</i> Panel discussion
			Break
22:10-22:40	16:10-16:40	12:10-12:40	Meet-the-expert session - Implementation patterns and challenges in HF care: insights from the EVOLUTION HF study <i>Chair: Orly Vardeny, Minnesota, MN, USA</i> Inertia, initiation and uptitration of GMDT: the EVOLUTION HF study <i>Gianluigi Savarese Stockholm, Sweden</i> <i>Supported by an educational grant from AstraZeneca</i>
			Break
			Session 4 - Guidelines implementation for acutely ill patients <i>Chairs: Stephan von Haehling, Göttingen, Germany, & Mehriban Isgandar, Baku, Azerbaijan</i> Uptitrating the foundational HF therapies <i>Alexandre Mebazaa, Paris, France</i> Where to start: is the hospital the best place? <i>Adriaan Voors, Groningen, The Netherlands</i> What can telehealth options provide? <i>Marat Fudim, Durham, NC, USA</i> What about cost issues? <i>Vijay Chopra, New Dehli, India</i> Panel discussion
			Part 3
			Session 5 - Mineralocorticoids antagonists in CRM disease <i>Chairs: Javed Butler, Jackson, MS, USA & Sunil Bandhari, Edinburgh, UK</i> Steroidal and nonsteroidal MRA structure and function – all the same? <i>Edgar V. Lerma, Evergreen Park, IL, USA</i> Antihypertensive effects of MRAs <i>Faiez Zannad, Nancy, France</i> Kidney effects of MRAs <i>Janani Rangaswami, Washington, D.C., USA</i> MRAs for prevention and treatment of heart failure <i>Gerasimos Filippatos, Athens, Greece</i> Panel discussion
02:10-02:50	20:10-20:50	16:10-16:50	Break
			Meet-the-expert session - Single pill combination (SPC) in Cardiorenal metabolic (CRM) disease <i>Stefan D. Anker, Berlin, Germany & Muthiah Vaduganathan, Boston, MA, USA</i>
			Break
			Session 6: Diuretics: old drugs, new data, new approaches <i>Chairs: Nisha Bansal, Seattle, WA, USA</i> Return to the nephron - mechanism of action of diuretics <i>Christopher Wilcox, Washington, DC, USA</i> Diuretics to treat acute decompensated heart failure <i>Wilfried Mullens, Ghent, Belgium</i> Diuretics to treat hypertension <i>Areef Ishani, Minneapolis, MN, USA</i> Can devices therapy make a difference? <i>William T. Abraham, Columbus, OH, USA</i> Panel discussion
03:00-04:00	21:00-22:00	17:00-18:00	

March 25, 2023 (Day 2)

Bangkok Time (ICT)	Paris Time (CET)	Rio Time (BRT)	Part 4
15:00-16:00	09:00-10:00	05:00-06:00	Session 7 - CRM drug management in patients with low eGFR and type 2 diabetes <i>Chairs: John Atherton, Brisbane, Australia & Petar Seferovic, Belgrade, Serbia</i>
			When should we STOP ACEi? <i>John Cleland, Glasgow, UK</i>
			Blood pressure targets and agents for patients with very low eGFR <i>Michael Böhm, Homburg, Germany</i>
			Practical considerations for use of SGLT2i with low eGFR <i>Meg Jardine, Sydney, Australia</i>
			GLP1RA – just what’s needed for patients with CKD? <i>Daniël van Raalte, Amsterdam, The Netherlands</i>
16:10-16:50	10:10-10:50	06:10-06:50	Panel discussion
			Break
			Satellite symposium - Management of CKD without diabetes – SGLT2 inhibitors, the new standard of care <i>Chair: Michel Jadoul, Brussels, Belgium</i>
			Burden of CKD without diabetes <i>Michel Jadoul, Brussels, Belgium</i>
			Role of SGLT2 inhibitors in non-diabetic CKD – supporting evidence <i>David Wheeler, London, UK</i>
17:00-18:00	11:00-12:00	07:00-08:00	SGLT2 inhibitors – a new standard of care for CKD without diabetes <i>Pinar Topsever, Istanbul, Turkey</i>
			Panel discussion
			<i>Supported by an educational grant from AstraZeneca</i>
			Break
			Session 8 - Diabetes and cardio-renal disease: the relevance of early treatment with the right drug <i>Chairs: Peter Rossing, Copenhagen, Denmark & Antonio Ceriello, Barcelona, Spain</i>
20:20-20:50	14:20-14:50	10:20-10:50	The legacy effect of early intensive management in diabetes <i>Francesco Prattichizzo, Milan, Italy</i>
			The evidence in favor of an early use of SGLT-2i and GLP-1RA <i>Apostolos G. Tsapas, Thessaloniki, Greece</i>
			The new ADA-EASD consensus <i>Melanie J. Davies, Leicester, UK</i>
			Heart failure is the ultimate problem: how to manage? <i>John McMurray, Glasgow, UK</i>
			Panel discussion
21:00-22:00	15:00-16:00	11:00-12:00	Part 5
			Meet-the-expert session - Management of hyperkalemia in cardiorenal disease – practical guidance and novel therapeutic options <i>Gianluigi Savarese, Stockholm, Sweden & Jolanta Malyszko, Warsaw, Poland</i>
			<i>Supported by an unrestricted educational grant by CSL Vifor</i>
			Break
			Session 9 - Managing “metals” <i>Chairs: Javed Butler, Jackson, MS, USA & Shelley Zieroth, Winnipeg, MB, Canada</i>
22:10-22:50	16:10-16:50	12:10-12:50	Anemia in CRM disease: update 2023 <i>Iain Macdougall, London, UK</i>
			Iron deficiency in CRM disease: update 2023 <i>John Cleland, Glasgow, UK</i>
			Hyperkalemia in CRM disease: update 2023 <i>Matthew R. Weir, Baltimore, MD, USA</i>
			Potassium management with finerenone or SGLT2i <i>Paola Fioretto, Padova, Italy</i>
			Panel discussion
23:00-00:00	17:00-18:00	13:00-14:00	Break
			Satellite symposium - Management of Hyperkalemia across the cardiorenal spectrum <i>Chair: Matthew R. Weir, Baltimore, MD, USA</i>
			The challenge of hyperkalemia in cardiorenal disease <i>Andrew J. S. Coats, Melbourne, VIC, Australia</i>
			Best practice recommendations for hyperkalemia management: across the cardiorenal spectrum <i>Shelley Zieroth, Winnipeg, Canada</i>
			Enabling guideline-recommended RAASi therapy to protect the heart and the kidneys <i>Kieran McCafferty, London, UK</i>
01:00-02:00	19:00-20:00	15:00-16:00	Panel discussion
			<i>Supported by an educational grant from AstraZeneca</i>
			Break
			Session 10 - Management of diabetes with kidney disease <i>Chairs: Peter Rossing, Copenhagen, Denmark & Sankar Navaneethan, Houston, TX, USA</i>
			How to manage glucose <i>M. Luiza Caramori, Cleveland, OH, USA</i>
02:10-02:50	20:10-20:50	16:10-16:50	How to manage kidney risk <i>Ian de Boer, Seattle, WA, USA</i>
			How to handle CV risk <i>Erin D. Michos, Baltimore, MD, USA</i>
			How to bring it together <i>Peter Rossing, Copenhagen, Denmark</i>
			Panel discussion
			Part 6
03:00-04:00	21:00-22:00	17:00-18:00	Session 11 - Managing frail and elderly patients <i>Chairs: Mitja Lainscak, Ljubljana, Slovenia & Fauto Pinto, Lisbon, Portugal</i>
			Cachexia, sarcopenia, frailty and aging: update 2023 <i>Mitja Lainscak, Ljubljana, Slovenia</i>
			The diabetologist’s point of view <i>A. Enrique Caballero, Boston, MA, USA</i>
			The nephrologist’s point of view <i>Cynthia Delgado, San Francisco, CA, USA</i>
			The cardiologist's point of view <i>Ambarish Pandey, Dallas, TX, USA</i>
02:10-02:50	20:10-20:50	16:10-16:50	Panel discussion
			Break
			Meet-the-expert session - Management of heart failure in real world clinical practice – insights from the REWOLUTION HF surveys
			<i>Andrew J. S. Coats, Melbourne, Australia & Ewa Jankowska, Wrocław, Poland</i>
			Break
03:00-04:00	21:00-22:00	17:00-18:00	Session 12 - Managing end-stage disease: focus on QoL <i>Chairs: Kerri L. Cavanaugh, Nashville, TN, USA & Fauto Pinto, Lisbon, Portugal</i>
			QoL assessment in CRM disease: update 2023 <i>John A. Spertus, Kansas City, MO, USA</i>
			The diabetologist’s point of view <i>Giuseppe Paolisso, Naples, Italy</i>
			The nephrologist’s point of view <i>Manjula Kurella Tamura, Stanford, CA, USA</i>
			The cardiologist's point of view <i>Suzanne V. Arnold, Kansas City, MO, USA</i>
			Panel discussion